{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Table 2', 'Predicted steady state systemic exposure and multiples of blood ex', 'vivo CXCL1-induced pharmacology following twice daily of', 'administration of danirixin', 'Dose', 'Predicted# steady-state median (5th 95th', 'Cavg', 'Cmin', '(mg)', 'percentile)', 'multiple of', 'multiple of', 'AUC(0-24)', 'Cavg', 'Cmin', 'IC50*', 'IC50*', 'steady-state', '(ng/mL)', '(ng/mL)', '(ug.h/mL)', '35', '9.59', '399', '192', '5.1', '2.4', '(4.70,1 19.3)', '(196,806)', '(47.6, 630)', '#Model derived based on PK data in healthy elderly participants from GSK Study No. 201037', '(GlaxoSmithKline Document Number. 2015N248339_00).', '*Model predicted population mean IC50=78.5 ng/mL (95% CI: 37.3, 120), sigmoidal Emax model of DNX', 'PK-ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils in healthy participants.', '6.', 'STUDY POPULATION', 'This study will identify specific patients most likely to decline from the well established', 'COPDGene cohort [NCT00608764] This study will be an ancillary study within', 'COPDGene investigating the enrichment strategy for assessing disease progression.', 'These potential participants have been identified by COPDGene investigators based on', 'data collected over the initial 5 year period. The participants were identified based on a', 'Random Forest analysis and a demonstrated decline of at least 20mL/yr over the initial 5', 'year period. Once participants are identified from the COPDGene dataset, the following', 'criteria will be verified at initial study visit following signing of consent.', 'Prospective approval of protocol deviations to recruitment and enrolment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '6.1.', 'Inclusion Criteria', 'Participants are eligible to be included in the study only if all of the following criteria', 'apply:', 'Age', '1.', 'Participant must be 40 to 76 years of age inclusive, at the time of signing the', 'informed consent.', 'Type of Participant and Disease Characteristics', '2.', 'At the screening visit, the subject must have an FEV1 >40% of the predicted normal.', '3.', 'Participants with a prior history of asthma are eligible if they have a current', 'diagnosis of COPD', '24']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Weight', '4.', 'Body weight 45 kg', 'Sex', '5.', 'Male or female', 'Female participants:', 'A female participant is eligible to participate if she is not a woman of childbearing', 'potential (WOCBP) as defined in Section 12.5 (Appendix 5)', 'Informed Consent', '6. Capable of giving signed informed consent as described in Section 12.3 (Appendix 3)', 'which includes compliance with the requirements and restrictions listed in the', 'informed consent form (ICF) and in this protocol.', '6.2.', 'Exclusion Criteria', 'Participants are excluded from the study if any of the following criteria apply:', 'Medical Conditions', '1. Diagnosis of other clinically relevant lung disease (other than COPD), e.g.', 'sarcoidosis, tuberculosis, pulmonary fibrosis, severe bronchiectasis or lung cancer', '2. COPD due to alpha-l-antitrypsin deficiency', '3. Pulse oximetry < 88% at rest at screening. Participants should be tested while', 'breathing room air. However, participants living at high altitudes (above 5000 ft or', '1500 m above sea level) who are receiving supplemental oxygen can be included', 'provided they are receiving the equivalent of < 4L/min and screening oximetry is', 'measured while on their usual settings.', '4. Less than 14 days have elapsed from completion of a course of antibiotics or oral', 'corticosteroids for a recent COPD exacerbation', '5. Participants with a peripheral blood neutrophil count < 1 X 109/L', '6. Diagnosis of pneumonia (chest X-ray or CT confirmed) within the 3 months prior to', 'screening', '7. Chest X-ray (posterior with lateral) or CT scan reveals evidence of a clinically', 'significant abnormality not believed to be due to the presence of COPD (historic data', 'up to 1 year may be used).', '8. History or current evidence of clinically significant renal disease, diabetes', 'mellitus/metabolic syndrome, hypertension, or any other clinically significant', 'cardiovascular, neurological, immunological, endocrine, or haematological', 'abnormality that is uncontrolled on permitted therapies. Significant is defined as any', 'disease that, in the opinion of the Investigator, would put the safety of the participants', '25']\n\n###\n\n", "completion": "END"}